'Nanocircles' act as Trojan horse to shut down disease-causing genes, study finds

January 24, 2002

Stanford scientists have synthesized a molecule of DNA that is capable of shutting off specific genes in living bacteria. Dubbed the "nanocircle," the new nanometer-size molecule might one day give researchers the ability to target harmful genes that cause cancer and other diseases in humans.

"In the long range, we hope that nanocircles could be used for genetic therapy in people," said Eric T. Kool, a professor of chemistry at Stanford who led the nanocircle study.

The results were published in the Jan. 8 issue of the Proceedings of the National Academy of Sciences (PNAS) in a paper co-authored by Kool, former postdoctoral fellow Tatsuo Ohmichi and graduate student Angéle Maki.

Rolling circles

Kool helped pioneer nanocircle technology in 1991 while at the University of Rochester, where he synthesized the first circular DNA molecules capable of replicating themselves in a test tube when combined with special DNA-copying enzymes and other chemicals.

The technique - known as "rolling circle amplification" - is now one of the hottest fields in biotechnology, because it offers the potential to produce and detect more copies of a specific DNA sequence faster and cheaper than other methods.

"What is new about the PNAS study is that, for the first time, we used a nanocircle in a living cell - the bacterium E. coli," Kool noted.

He and his colleagues wanted to see if a synthetic molecule of circular DNA could target a specific gene in E.coli. To do that, they needed to design a DNA nanocircle that could duplicate large numbers of ribozymes - enzymes found in all living cells that are capable of altering the function of individual genes in the organism's DNA. Ribozymes are made of RNA - protein-producing molecules manufactured by genes.

"Ribozymes are biologically active," Kool said. "They can inhibit or shut down a gene by destroying its RNA."

In nature, ribozymes are assembled by DNA molecules, which act as templates. First, the DNA binds with an enzyme called RNA polymerase, then the ribozyme is formed. The challenge for researchers was to figure out which synthetic nanocircle was best suited for binding with the naturally existing RNA polymerase in the bacterial cell.

"RNA polymerases are picky, so the real trick was making a nanocircle that was especially good," Kool noted. "We said, 'Let's let the RNA circles tell us which polymerase they like best - let them tell us who the winner is, and then we'll know which circle is best.'"

The researchers ended up making 15 generations of nanocircles until they finally came up with the best DNA sequence.

"It was evolution in a test tube," Kool recalled.

The chosen nanocircles were then added to the E. coli to determine if the mixture would produce ribozymes capable of cleaving a specific drug-resistant gene in the bacteria.

The results were clear: The targeted gene stopped functioning more than 90 percent of the time.

Trojan horse

"Our study demonstrated that nanocircles can act like a Trojan horse," Kool said. "They enter cells and start producing ribozymes that can be targeted against a particular gene. But the nanocircle itself does not replicate itself and eventually leaves the cell."

Kool's goal is to create nanocircles that can inhibit disease-causing and mutant genes in people that could be used to treat a variety of illnesses from AIDS to cancer. As a first step, his lab is developing nanocircles that will shut down genes in tiny worms called nematodes.

"We also would like to see if we can use nanocircles to eliminate a harmful bacterium or virus by shutting down an essential gene inside the organism itself - a true Trojan horse," Kool added.

He also noted that nanocircle technology could prove less expensive than making ribozymes directly and adding them to cells - because relatively small numbers of nanocircles can produce thousands of ribozymes.

The PNAS study was funded by the U.S. Department of Defense Breast Cancer Research Program, administered by the U.S. Army.
CONTACT: Mark Shwartz, News Service, 650-723-9296; mshwartz@stanford.edu

COMMENT: Eric T. Kool, Department of Chemistry, 650-724-4741; kool@stanford.edu

EDITORS: The study, "Efficient bacterial transcription of DNA nanocircle vectors with optimized single-stranded promoters," is available from the Proceedings of the National Academy of Sciences at http://www.pnas.org.

Relevant Web URL: http://www.stanford.edu/group/kool/main.html

Stanford University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.